Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016)

Population structure of Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil: emergence and expansion of the MDR serotype 6C-CC386 lineage

(2018) Felipe P G Neves et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016

(2018) Walter H.B. Demczuk et al.   VACCINE

Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention

(2018) Lavida R. K. Brooks et al.   Frontiers in Immunology

Streptococcus pneumoniae serotype 19A: worldwide epidemiology

(2017) Raul Isturiz et al.   Expert Review of Vaccines

Genomic Epidemiology of Penicillin-Nonsusceptible Pneumococci with Nonvaccine Serotypes Causing Invasive Disease in the United States

(2017) Cheryl P. Andam et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

(2017) Evelyn Balsells et al.   PLoS One

Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA

(2016) B.J. Metcalf et al.   CLINICAL MICROBIOLOGY AND INFECTION

Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacement

(2016) William P Hausdorff et al.   Human Vaccines & Immunotherapeutics

Characterization of MDR and XDRStreptococcus pneumoniaein Canada, 2007–13

(2015) Alyssa R. Golden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States

(2014) Sandra S. Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains ActiveIn Vitroamong β-Lactam Agents

(2014) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine

(2014) Rodrigo E. Mendes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-NonsusceptibleStreptococcus pneumoniae

(2014) Ron Dagan et al.   JOURNAL OF INFECTIOUS DISEASES

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011)

(2012) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period

(2010) J. Liñares et al.   CLINICAL MICROBIOLOGY AND INFECTION